UTHR vs VTRS
United Therapeutics vs Viatris — AI-powered side-by-side comparison
UTHR
United Therapeutics
70
Buy
VS
| Metric | UTHR | VTRS |
|---|
| AI Score |
70
|
69
|
| Price |
$538.75
|
$16.41
|
| P/E Ratio |
17.82×
|
-45.64×
|
| ROE |
18.8%
|
-23.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
86.1%
|
34.8%
|
| Debt / Equity |
0.00×
|
0.94×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
66.9
|
31.0
|
| Beta |
0.58
|
0.902
|
| Expected Upside |
+4.6%
|
+0.3%
|
AI Committee View
Current Innellis committee reasoning for UTHR versus VTRS.
UTHR leads by 1 points.
UTHR scores 70/100 (Buy) versus VTRS at 69/100 (Buy).
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 15.0% downside vs 4.6% upside.
VTRS Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical